

Claims:

1. The use of alprostadil for producing a medicament for angioneogenesis.
- 5 2. The use as claimed in claim 1, characterized in that the angioneogenesis is employed within the framework of the treatment of chronic heart failure and/or cardiomyopathy.
- 10 3. The use as claimed in claim 1, characterized in that the angioneogenesis is employed within the framework of a neovascularization.
- 15 4. The use as claimed in claim 1, characterized in that the angioneogenesis is used to reduce the degree of fibrosis.
- 20 5. The use as claimed in claim 1, characterized in that the angioneogenesis is used for regression of hypertrophy.
- 25 6. The use as claimed in claim 1, characterized in that the angioneogenesis for revitalization of dead areas of the heart, especially after a myocardial infarction.
- 30 7. The use as claimed in claim 1, characterized in that the angioneogenesis is used for the treatment of advanced peripheral arterial occlusive diseases.
- 35 8. The use as claimed in claim 1, characterized in that the angioneogenesis is used for the treatment of diabetic angiopathy.
9. The use as claimed in claim 1, characterized in that the angioneogenesis is used for the treatment of systemic lung disorders, especially pulmonary fibrosis.

10. The use as claimed in claim 1, characterized in that the angioneogenesis is used for the treatment of acute or chronic renal failure and glomerulonephritis.

5

11. The use as claimed in claim 1, characterized in that the angioneogenesis is used for the treatment of acute or chronic hepatic failure.

10 12. The use as claimed in claim 1, characterized in that the angioneogenesis is used for the treatment of cerebral infarction.